FDA reverses course, will review Moderna’s mRNA-based flu shot

FDA’s see-sawing on Moderna’s new mRNA flu vaccine is dangerous (Editorial)

The anti-science, anti-medicine mindset of Health and Human Services Secretary Robert F. Kennedy Jr. is killing people by quashing life-saving vaccines. There is no other explanation why Moderna’s paperwork to the U.S. Food and Drug Administration for its new mRNA flu vaccine was initially rejected, citing supposed faults with the study the pharma giant had already conducted into the drug. The FDA has since reversed course and agreed to review t…

FDA Reopens the Door to Moderna’s mRNA Flu Shot

Following a swiftly arranged meeting between the FDA and Moderna, the agency reconsidered last week's refusal of the company's filing. ... The post FDA Reopens the Door to Moderna’s mRNA Flu Shot appeared first on The New American.

Moderna (NASDAQ:MRNA) Shares Gap Up Following Analyst Upgrade

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) gapped up before the market opened on Wednesday after The Goldman Sachs Group raised their price target on the stock from $36.00 to $41.00. The stock had previously closed at $43.93, but opened at $46.69. The Goldman Sachs Group currently has a neutral rating on the stock. Moderna shares last traded at $46.5050, with a volume of 6,606,457 shares trading hands. MRNA has been the subject of a number of…

Moderna Spikes After FDA’s About-Face on mRNA Flu Vaccine

That was an unexpected and much-needed shot in the arm for Moderna. On Wednesday, the US Food and Drug Administration announced it would begin reviewing the biotech firm’s new mRNA-based flu vaccine — just a week after the agency initially rejected Moderna’s application, citing flaws in the company’s research design. The reversal is not just a major win for Moderna, but the entire vaccine-making industry, which has struggled in an era of a, shal…

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

Federal health officials have raised safety concerns about mRNA vaccines, although they have provided no credible data on health risks. NurPhoto via Getty ImagesThe Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts. But just a week later, on Feb. 18, the FDA backtracked on its decision…

FDA reverses course, will review Moderna’s flu vaccine application | Honolulu Star-Advertiser

Moderna said today the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling drugmaker and investor concerns over policy changes at the agency under President Donald Trump.